Latest 10-Q quarterly reports

BridgeBio Oncology Therapeutics, Inc. reported increased operating expenses and net losses for the second quarter of 2026, driven by expanded research and development activities for its lead product candidates.

Neutron Holdings, Inc. (Lime) reported strong revenue growth and a significant turnaround in net income following its IPO, driven by fleet expansion and increased ridership.

Global Arena Holding, Inc. filed its Q3 2025 10-Q, showing increased revenues but also persistent operating losses and a substantial accumulated deficit, raising going concern doubts.

Immunome, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased operating expenses and net losses, alongside progress in its oncology therapy pipeline.

Energy Vault Holdings, Inc. announced its second quarter 2026 financial results, showing a substantial increase in revenue driven by energy storage product sales and tolling agreements, but also reporting continued net losses and increased debt.

NextNav Inc. filed its Q2 2026 quarterly report, detailing continued net losses and operational expenses, alongside significant cash inflows from warrant exercises.

Absci Corporation's Q2 2026 filing reveals a widening net loss and increased R&D expenses, though positive interim data for its lead candidate ABS-201 offers a glimmer of progress.

Anterix Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting a decrease in net income driven by a significant reduction in non-cash gains from intangible asset exchanges compared to the prior year, alongside improved operating cash flow and continued customer contract activity.

Pliant Therapeutics filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses and operational adjustments, while advancing its PLN-101095 oncology program.

Gain Therapeutics reported continued net losses and a significant cash burn, raising substantial doubt about its ability to continue as a going concern, even as its lead Parkinson's drug candidate, rexaceract, progresses through clinical trials.

Hoyne Bancorp, Inc. reported a slight decrease in net income for Q2 2026 compared to Q2 2025, driven by increased noninterest expenses, though net interest income saw improvement.

Dermata Therapeutics reports a net loss of $2.97 million for Q2 2026, faces going concern uncertainty, and is engaged in significant litigation with a former licensor, while preparing for its Tome skincare product launch.

Kyverna Therapeutics announced a First Amendment to its Loan and Security Agreement, extending loan availability and outlining new covenants, while also providing updates on its CAR T therapies for autoimmune diseases.

IZEA Worldwide's Q2 2026 filing reveals a 36% year-over-year revenue decrease, driven by a strategic shift and market softness, resulting in a net loss.

Revvity, Inc. announced its second-quarter fiscal year 2026 results, showcasing a 1% revenue increase driven by its Diagnostics segment, while navigating a slight decrease in its Life Sciences segment.

Bolt Biotherapeutics, Inc. reported a net loss of $7.7 million for Q2 2026 and faces substantial doubt about its ability to continue as a going concern.

SINTX Technologies reported increased revenue for Q2 2026, but also highlighted substantial doubt about its ability to continue as a going concern, alongside significant operating losses.

iShares Bitcoin Premium Income ETF's Q2 2026 filing shows a net decrease in assets, primarily driven by unrealized losses on bitcoin and IBIT shares, partially offset by premiums from options written.

The iShares Staked Ethereum Trust ETF experienced a significant decline in net asset value per share during the second quarter of 2026, primarily driven by a decrease in the price of ether.

AN2 Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued investment in research and development, progress in clinical trials for epetraborole and AN2-502998, and a strong cash position.

Velo3D, Inc. filed its Q2 2026 10-Q, showing significant revenue growth but also substantial operating losses and a continued going concern warning, despite recent capital raises.

United States Antimony Corporation reported a net loss for the second quarter of 2026, with revenues declining significantly in its primary antimony segment, though its zeolite business showed strong growth.

Public Policy Holding Company reported a 7.3% increase in Q2 revenue to $52.1 million, driven by acquisitions and organic growth, while net losses narrowed.

Spectral AI, Inc. announced its Q2 2026 financial results, highlighting FDA De Novo classification for its DeepView System, while revenue declined and net loss widened.

High Roller Technologies, Inc. filed its Form 10-Q for the period ended June 30, 2026, reporting a substantial decrease in net gaming revenue and an increased net loss, alongside progress in securing a prediction market license.

Gladstone Land Corporation's Q2 2026 Form 10-Q filing reveals a net loss of $12.8 million for the six months ended June 30, 2026, a significant increase from the prior year, alongside a decrease in total lease revenues.

Cardiff Oncology's Q2 2026 report highlights ongoing litigation with NMS, substantial doubt about its going concern status, and a registered direct offering to raise capital, alongside promising clinical trial updates for onvansertib.

Smart Sand, Inc. announced a substantial increase in revenue and gross profit for the second quarter of 2026, driven by higher sales volumes and slightly improved pricing.

SELLAS Life Sciences Group reports increased cash reserves and positive clinical trial developments for its cancer therapeutics, alongside continued operational losses.

Worksport Ltd. reported increased net sales for the second quarter of 2026, but also a widening net loss and significant cash burn, raising concerns about its going concern status.